Company intelligence / Profile preview
Reviva Pharmaceuticals
- Ownership
- Public · RVPH
- Development stage
- Other
Overview
Reviva’s lead candidate brilaroxazine has demonstrated robust efficacy and safety in both Phase 2 and pivotal Phase 3 trials for schizophrenia. The RECOVER Phase 3 trial met all primary and secondary endpoints with statistically significant improvements across major symptom domains. Long-term open-label extension data show sustained efficacy over one year with favorable tolerability. NDA submission targeted for late 2026[1][3][8].
- Therapeutic areas
- PsychiatryCardiovascularMetabolic DisordersImmunologyNeurology
- Modalities
- small molecules (new chemical entities)[1][2][7]
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Partnerships
Financials
- Market cap
- $4.5M
- Total revenue
- $0
- Enterprise value
- $-19.7T
Beyond the preview
Go deeper on Reviva Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Reviva Pharmaceuticals.